Abstract 533P
Background
Docetaxel (DTX) + ramucirumab (RAM) is one of the standard treatment options in second-line setting after first-line platinum-based chemotherapy plus ICI. The SCORPION study, phase II trial evaluating the efficacy and safety of DTX plus RAM after first-line platinum-based chemotherapy plus ICI, demonstrated encouraging antitumor activity with a manageable safety profile. However, the clinical benefit of RAM in elderly patients is not fully elucidated. Here, we report the subset analysis of the elderly patients in SCORPION study.
Methods
The primary end point of the study was objective response rate (ORR), and secondary endpoints were disease control rate (DCR), progression-free survival (PFS), and safety etc. Patients were treated with 60 mg/m2 of DTX and 10 mg/kg of RAM on day 1 with strong recommendation of pegfilgrastim on day 2 every 3 weeks.
Results
Thirty-three patients were recruited from 8 institutions. Median age (range) was 66 (42–79) y, 15 patients (45%) were aged ≤ 65, while 6 (18%) were aged ≥ 75. As previously reported, the primary endpoint was met as 11 of 32 patients achieved PR with ORR at 34.4% (80%CI, 23.1-47.2), and median PFS was 6.5 months. In elderly patients with aged ≥ 75 years, the ORR and disease control rate were 16.7 % and 100%, respectively (1 in 6 pts had a PR and all 6 pts had their disease controlled). Median PFS was 8.5 months. No treatment-related deaths and no new safety signals were observed in elderly patients aged ≥ 75 years.
Conclusions
DTX plus RAM showed favorable DCR with 8.5 months of PFS in elderly patients aged ≥ 75 years. Although our analysis was based on small subset, DTX plus RAM could be a treatment option even in elderly patients who failed first-line platinum-based chemotherapy plus ICI.
Clinical trial identification
jRCTs041190077.
Editorial acknowledgement
Legal entity responsible for the study
Masahiro Morise.
Funding
Eli Lilly Japan K.K.
Disclosure
T. Yamaguchi: Financial Interests, Personal, Speaker’s Bureau: Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, Bristol-Myers Squibbb. R. Matsuzawa: Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical. M. Morise: Financial Interests, Institutional, Research Grant: Boehringer Ingelheim, Eli Lilly; Financial Interests, Personal, Speaker’s Bureau: Eli Lilly, Chugai, AstraZeneca, Ono, Pfizer, MSD; Non-Financial Interests, Personal, Non financial benefits: F. Hoffmann-La Roche; Financial Interests, Institutional, Local PI: Chugai, AstraZeneca, Ono, Pfizer, Merk Serono, Kissei, Taiho, Novartis. K. Ito: Financial Interests, Personal, Speaker’s Bureau: Boehringer Ingelheim, AstraZeneca, Pfizer, Eli Lilly, Chugai Pharmaceutical, MSD, Ono Pharmaceutical, Taiho Pharmaceutical, Takeda, Daiichi Sankyo. O. Hataji: Financial Interests, Institutional, Research Grant: AstraZeneca, Novartis, MSD, Daiichi Sankyo, Bayer Yakuhin, AbbVie, Eli Lilly, Janssen, Ono; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Chugai, Takeda, MSD, Merck, Daiichi Sankyo, Eli Lilly, AbbVie, Boehringer Ingelheim, Nippon Kayaku, Taiho. K. Takahashi: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, GSK, MSD, Nippon Kayaku, Novartis, Pfizer, Taiho, Takeda. Y. Goto: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical CO., LTD, Nippon Boehringer Ingelheim CO., LTD., Chugai Pharmaceutical CO., LTD., Chugai Pharmaceutical CO., LTD., MSD K.K., AstraZeneca K.K., GSK K.K., Pfizer Japan Inc., Takeda Pharmaceutical CO., LTD., Nippon Kayaku Co., Ltd., Novartis Japan, Bristol Myers Squibb K.K., KYOWA HAKKO BIO CO., Ltd., Eli Lilly Japan K.K. H. Itani: Financial Interests, Personal, Speaker’s Bureau: Eli Lilly. Y. Zenke: Financial Interests, Personal, Invited Speaker: AstraZeneca, Lilly, Chugai, Boehringer Ingelheim, Ono pharmaceutical, Bristol Myers Squibb, Takeda pharmaceutical, Taiho pharmaceutical, MSD, Novartis, Nippon Kayaku, Amgen, Kyowa-Hakko Kirin; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Merck, Daiichi Sankyo, Amgen. M. Oki: Financial Interests, Institutional, Research Grant: AbbVie, Chugai, GSK, MSD, Parexel, Sanofi, AstraZeneca, Fujifilm Toyama Chemical, Janssen, Ono and Pfizer; Financial Interests, Personal, Speaker’s Bureau: AMCO, Canon Medical Systems, Fujifilm Toyama Chemical, Merit Medical Japan, Olympus, AstraZeneca, Chugai, Kaneka Medix, Novartis, and Sanofi. M. Ishii: Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, GSK, Pfizer, Shionogi, Sanofi, Insmed, Asahi Kasei Pharma, Kyorin pharmaceutical, Chugai pharmaceutical, Boehringer Ingelheim, Eli Lilly, Daiichi Sankyo, MSD, Abbott, Taiho pharmaceutical, Amgen, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract
281P - 10-year treatment outcome of prostate cancer patients with 3D conformal radiation: Experience of a single cancer institution in Iran
Presenter: Reyhane Bayani
Session: Poster Display
Resources:
Abstract
282P - Predictors of outcomes in patients with clinically lymph node-positive prostate cancer after definitive radiotherapy
Presenter: Jae-Sung Kim
Session: Poster Display
Resources:
Abstract
283P - Radiotherapy utilization rate and treatment patern of protate cancer at Cipto Mangunkusumo Central General Hospital (RSCM): What we learn from pre-pandemic era
Presenter: Riyan Apriantoni
Session: Poster Display
Resources:
Abstract
284TiP - CYCLONE 3: A phase III, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer
Presenter: Nobuaki Matsubara
Session: Poster Display
Resources:
Abstract
292P - Comparative characteristics of early cervical cancer diagnosis methods for Tashkent women
Presenter: Gulnoza Goyibova
Session: Poster Display
Resources:
Abstract
293P - Carboplatin in locally advanced cervical cancer treated with chemoradiation: An alternative to cisplatin
Presenter: Natalia Isabel Valdiviezo Lama
Session: Poster Display
Resources:
Abstract
294P - Concurrent chemoradiation with cisplatin every 3 weeks in locally advanced cervical cancer: A single arm phase II clinical trial
Presenter: Long Nguyen
Session: Poster Display
Resources:
Abstract
295P - A prospective study of dose escalated simultaneous integrated boost in node-positive cervical cancer
Presenter: Ritusha Mishra
Session: Poster Display
Resources:
Abstract
296P - Safety, efficacy, and immunogenicity of therapeutic vaccines for patients with high-grade cervical intraepithelial neoplasia (CIN 2/3) associated with human papillomavirus: A systematic review
Presenter: Caroline Amélia Gonçalves
Session: Poster Display
Resources:
Abstract